“…For example, T‐DM1 (Kadcyla; Genentech/Roche, South San Francisco, CA, USA) is currently approved by the European Medical Agency (EMA) and FDA for patients with HER2‐positive metastatic breast cancer. Additionally, IMGN853 (Immunogen, Waltham, MA, USA) has already demonstrated high preclinical activity against type II endometrial cancer and other solid tumors (Ab et al , ; Altwerger et al , ; English et al , ; Nicoletti et al , ).…”